"First To File" Policy Increases Generics Qualifying For 180-Day Exclusivity
Executive Summary
FDA's shift in policy to awarding 180-day exclusivity to the first generic applicant to file, rather than to the first company to successfully challenge a patent, has significantly increased the number of generics qualifying for the exclusivity.
You may also be interested in...
Brand/Generic Settlements Return To Capitol Hill
Apotex could make its case for scrapping first-to-file exclusivity during a hearing in Rep. Rush’s subcommittee.
Brand/Generic Settlement Reform Will Be Balancing Act For Congress
Development of legislation to address settlements between brand and generic companies will need to ensure that commercial incentives remain for generic firms to challenge patents
Brand/Generic Settlement Reform Will Be Balancing Act For Congress
Development of legislation to address settlements between brand and generic companies will need to ensure that commercial incentives remain for generic firms to challenge patents